Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Shanthi Rexaline

2 Natural-Killer Cell Therapy Oncology Companies Investors Should Watch

Natural-killer cell therapy is one of the most recent paradigms in cancer treatment, and two prominent companies working on this new technology are Fate Therapeutics Inc (NASDAQ:FATE) and Century Therapeutics Inc (NASDAQ:IPSC), an analyst at BofA Securities said in a note on Tuesday.

The Biopharma Analyst: Tazeen Ahmad has a Buy rating and $112 price target on Fate shares.
The analyst rates Century a Buy with a $34 price target.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.